XETRACT
Market cap613mUSD
Dec 23, Last price
58.00EUR
1D
1.75%
1Q
29.46%
Jan 2017
-61.84%
Name
Alzchem Group AG
Chart & Performance
Profile
AlzChem Group AG, together with its subsidiaries, develops, produces, and trades chemical products in Germany, European Union, rest of Europe, Asia, NAFTA region, and internationally. It operates through three segments: Specialty Chemicals, Basics & Intermediates, and Other & Holding. The company offers dietary supplements under the Creapure and Alipure brands; preparation of guanidinoacetic acid as a nutritional feed additives under the Creamino brand; creatine dietary supplements under the LIVADUR brand; products for pharmaceuticals under the Bioselect brand; curing agents, including accelerators for use in adhesives, powder coatings, printed circuit boards, and composites under the DYHARD name; and silicon nitride for ceramics, and electronics and solar applications under the SILZOT brand. It also provides fine and specialty chemicals, including products based on calcium carbide, calcium cyanamide, hydrogen cyanamide, dicyandiamide, guanidine, guanamines, and nitroguanidine, as well as aromatic and aliphatic nitriles; calcium cyanamide under the PERLKA name; germicide for use in pig pens under the ALZOGUR name; plant growth regulators under the Dormex and Sitofex name; and plant protection additives under the BREAK-THRU name. In addition, the company offers products for use in hot metal desulfurization and secondary metallurgy applications; and technical gases. Further, it provides chemical park operations and administrative services, as well as produces and distributes various infrastructure services. AlzChem Group AG was founded in 1908 and is based in Trostberg, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | 2014‑12 | |
Income | ||||||||||
Revenues | 540,649 -0.29% | 542,223 28.40% | 422,293 11.35% | |||||||
Cost of revenue | 449,294 | 309,910 | 192,839 | |||||||
Unusual Expense (Income) | ||||||||||
NOPBT | 91,355 | 232,313 | 229,454 | |||||||
NOPBT Margin | 16.90% | 42.84% | 54.34% | |||||||
Operating Taxes | 13,397 | 11,059 | 8,748 | |||||||
Tax Rate | 14.66% | 4.76% | 3.81% | |||||||
NOPAT | 77,958 | 221,254 | 220,706 | |||||||
Net income | 34,621 15.20% | 30,052 8.91% | 27,593 40.11% | |||||||
Dividends | (10,685) | (10,136) | (7,821) | |||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | (1,013) | |||||||||
BB yield | ||||||||||
Debt | ||||||||||
Debt current | 10,446 | 68,115 | 12,295 | |||||||
Long-term debt | 57,032 | 38,449 | 50,944 | |||||||
Deferred revenue | 164,377 | |||||||||
Other long-term liabilities | 120,156 | 107,323 | 171 | |||||||
Net debt | 55,589 | 97,315 | 54,934 | |||||||
Cash flow | ||||||||||
Cash from operating activities | 72,671 | (4,240) | 43,016 | |||||||
CAPEX | (20,557) | (29,068) | (28,535) | |||||||
Cash from investing activities | (20,548) | (28,511) | (28,479) | |||||||
Cash from financing activities | (49,166) | 33,647 | (23,620) | |||||||
FCF | 151,437 | 85,152 | 207,528 | |||||||
Balance | ||||||||||
Cash | 11,883 | 9,618 | 8,731 | |||||||
Long term investments | 6 | (369) | (426) | |||||||
Excess cash | ||||||||||
Stockholders' equity | 248,676 | 224,741 | 204,824 | |||||||
Invested Capital | 346,203 | 345,425 | 300,891 | |||||||
ROIC | 22.54% | 68.47% | 73.73% | |||||||
ROCE | 25.92% | 66.23% | 75.24% | |||||||
EV | ||||||||||
Common stock shares outstanding | 10,176 | 10,136 | 10,147 | |||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | 117,255 | 257,856 | 253,928 | |||||||
EV/EBITDA | ||||||||||
Interest | 7,663 | 3,032 | 1,703 | |||||||
Interest/NOPBT | 8.39% | 1.31% | 0.74% |